Skip to Main Content

Paper Details

Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic predictor for EPO-increasing therapies.
Am J Hum Genet
3
2022
CAD, CKD, EPO, EPO promoter region, HIF, HIF-PHIs, Hypoxia-inducible factor prolyl hydroxylase, MI, anemia, cardiovascular disease, chronic kidney disease, cis-EPO variant, coronary artery disease, endogenous EPO, human, myocardial infarction, prolyl, rs1617640, stroke
Author NameAffiliation
Andrew R WoodUniversity of Exeter Medical School, University of Exeter, Royal Devon and Exeter NHS Trust
Peter J van der MostUniversity of Groningen, University Medical Center Groningen
Peter J van der MostUniversity of Groningen, University Medical Center Groningen
Toshiko TanakaNational Institute on Aging
Toshiko TanakaNational Institute on Aging
Mike A NallsNational Institute on Aging, USA Center for Alzheimer's and Related Dementias, National Institutes of Health
Mike A NallsNational Institute on Aging, USA Center for Alzheimer's and Related Dementias, National Institutes of Health
Niek VerweijUniversity of Groningen, University Medical Center Groningen
Harold SniederUniversity of Groningen, University Medical Center Groningen
Harold SniederUniversity of Groningen, University Medical Center Groningen
Paul J GallinsBioinformatics Research Center, North Carolina State University
Fred A WrightBioinformatics Research Center, North Carolina State University
Yi-Hui ZhouBioinformatics Research Center, North Carolina State University
Luigi FerrucciNational Institute on Aging
Luigi FerrucciNational Institute on Aging
Stefania Bandinelli
Stefania Bandinelli
Pim van der HarstUniversity Medical Center Utrecht
Vickas V PatelCollegeville
Dawn M WaterworthCollegeville
Audrey Y Chu
Timothy M FraylingUniversity of Exeter Medical School, University of Exeter, Royal Devon and Exeter NHS Trust
  • 1 - 22

Datasets